

Date: March 14, 2025.

To,

Corporate Relationship Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, **Mumbai-400 001**

Dear Sir/Madam,

Sub: Intimation U/R 30 of the SEBI(LODR) Regulations- Reg.

Ref: Stock Code: NSE: SHILPAMED/BSE-530549

Shilpa Medicare Limited

Corporate & Admin Office:

"Shilpa House", # 12-6-214/A-1, Hyderabad Road, Raichur – 584 135, Karnataka, India

Tel: +91-8532-238704, Fax: +91-8532-238876

Email: info@vbshilpa.com, Web: www.vbshilpa.com

CIN: L85110KA1987PLC008739

National Stock Exchange of India Ltd. Exchange Plaza, 5th Floor, Plot No.C/1, G Block Bandra Kurla Complex, Bandra (E) **Mumbai-400 051**

USFDA Inspection at Unit-2 of Shilpa Pharma Lifesciences Limited, a wholly owned subsidiary of Shilpa Medicare Limited.

This is to inform you that United States Food and Drugs Administration (USFDA) has conducted an inspection at Unit-2 of Shilpa Pharma Lifesciences Limited, located at Raichur from March 10-14, 2025.

The inspection was closed with ZERO observations. This is second consecutive ZERO 483 inspection from USFDA at this site.

For SHILPA MEDICARE LIMITED

Ritu Tiwary
Company Secretary & Compliance Officer